Four years after the Supreme Court’s landmark Dobbs v. Jackson Women’s Health Organization decision overturned Roe v. Wade, the American landscape for reproductive healthcare has fractured into a complex patchwork of access. While 13 states have enacted near-total bans on abortion, the remaining states—those where the procedure remains legal—face a different, less visible, but equally daunting hurdle: the economic viability of care for the nation’s most vulnerable patients.
A new analysis of Medicaid physician fee schedules reveals that even in states where abortion is legally protected, the federal and state reimbursement structures often fail to cover the true costs of medical services. This creates a de facto barrier to access for low-income patients, as providers grapple with financial shortfalls that threaten their ability to keep doors open.
Main Facts: The Financial Chasm
The core issue lies in the discrepancy between the cost of providing care and the amount state Medicaid programs are willing to reimburse. Under the federal Hyde Amendment, federal Medicaid funds are prohibited from being used for abortion services, except in limited cases involving rape, incest, or life endangerment.
However, 21 states have opted to bypass these federal restrictions by using their own state revenues to provide broader coverage for Medicaid enrollees. Despite this progressive policy, the "reimbursement gap" remains stark. Research indicates that Medicaid rates are historically lower than those offered by Medicare or private insurers. In many cases, these rates cover only a fraction of what a self-pay patient is charged, serving as a reliable proxy for the actual cost of operation.
For providers, the math is increasingly unsustainable. Abortion clinics must account for standard medical overhead—staff salaries, medical supplies, and administrative costs—while simultaneously absorbing the unique, high costs of security measures required to protect their staff and patients from anti-abortion harassment and violence.
A Chronology of Post-Dobbs Financial Strain
The trajectory of abortion financing has shifted dramatically since June 2022:
- 2022 (The Dobbs Decision): The Supreme Court ruling immediately triggers "trigger laws" in 13 states, ending abortion services there and shifting a massive influx of patients toward states with protective laws.
- 2023: The FDA removes in-person dispensing requirements for mifepristone, leading to a surge in medication abortion. By year’s end, medication abortion accounts for 65% of all U.S. abortions.
- 2024: Initial reports emerge detailing the widening gap between self-pay prices (averaging $563 for medication abortion) and Medicaid reimbursement.
- 2025: The U.S. Government Accountability Office (GAO) issues a report finding that 14 states are failing to comply with federal requirements to cover medication abortion even in the limited circumstances permitted under the Hyde Amendment.
- 2026: Recent data indicates that while some states (notably Pennsylvania, Colorado, and Maryland) have significantly increased their reimbursement rates, the majority of states have either kept rates stagnant or, in some cases, decreased them, failing to keep pace with healthcare inflation.
Supporting Data: By the Numbers
The disparity in reimbursement is not just a policy concern; it is a clinical one.
Medication Abortion
Medication abortion is often billed using a "global code" (HCPCS S0199) or via unbundled billing for separate components like mifepristone, misoprostol, and ancillary services like ultrasounds. In the 21 states providing state-funded access, the median reimbursement for the global code is $514. When all three components are summed, the median reimbursement is $597—a figure that often fails to account for the increasing reliance on telehealth and the associated administrative costs.
Procedural Abortions (D&C and D&E)
For Dilation and Curettage (D&C) procedures, typically used up to 16 weeks, the median reimbursement is $378. For Dilation and Evacuation (D&E) procedures, which are more complex and occur in the second trimester, the median rate is $636.
Crucially, the price difference between these two procedures is often negligible in many states. Three states—Rhode Island, Nebraska, and Wisconsin—reimburse at the exact same rate for both procedures, ignoring the reality that later-gestation procedures are significantly more resource-intensive.
Official Responses and Policy Failures
The Centers for Medicare and Medicaid Services (CMS) have faced pressure to address the non-compliance identified by the GAO. In late 2025, the GAO formally reported instances where state Medicaid programs were refusing to cover medication abortion drugs for patients whose cases met the narrow federal exceptions allowed under the Hyde Amendment.
Furthermore, state-level policy varies wildly. While states like Washington and New York have pushed to align their reimbursement structures more closely with real-world costs, others remain entrenched in outdated fee schedules. The reliance on abortion funds—non-profits that help patients cover the cost of their care—has become a structural necessity rather than a safety net. However, these funds are reporting depleted resources, as the post-Dobbs demand for financial assistance has far outstripped donor contributions.
Implications for the Future of Reproductive Access
The implications of these economic findings are profound. Insurance coverage, on paper, does not guarantee access if the reimbursement rate is so low that the provider loses money on every Medicaid patient they treat.
1. The Erosion of the Provider Workforce
When clinics lose money on every procedure, they are forced to make difficult operational decisions. This includes reducing the availability of certain procedures, limiting the number of Medicaid patients they accept, or, in extreme cases, closing their doors. The high cost of security—ranging from bulletproof glass to background checks—adds a layer of financial pressure that other medical practices do not face.
2. Widening Health Inequities
The Guttmacher Institute’s research highlights a clear class divide. In states that fund abortion beyond Hyde restrictions, 62% of patients use Medicaid. In contrast, 82% of patients in Hyde-restricted states pay out-of-pocket. This forces patients to engage in a desperate scramble for funds, often accruing high-interest debt or delaying care until they can scrape together the money—which, in turn, increases the gestational age of the pregnancy and the cost of the eventual procedure.
3. The Telehealth Disconnect
Telehealth has been a vital bridge for access, yet Medicaid reimbursement for these services remains inconsistent. While some states adopted temporary payment parity during the COVID-19 pandemic, many of these policies have since expired. Without permanent, robust parity, the promise of "accessible" telehealth abortion remains largely theoretical for those on Medicaid.
4. Conclusion
The current Medicaid reimbursement landscape is a testament to the fact that legalizing abortion is only the first step in ensuring access. The administrative reality—the "coding, billing, and reimbursement" side of medicine—is the quiet frontier where the battle for reproductive rights is being fought. Unless state Medicaid programs move toward more realistic, cost-adjusted reimbursement rates, the right to choose will continue to be a right that is financially accessible to the wealthy but increasingly out of reach for those who rely on the public safety net.
As the U.S. moves deeper into the post-Dobbs era, the sustainability of the abortion care workforce depends on policy change that acknowledges that medical care is not just a clinical service, but an economic one. Without systemic reform to reimbursement rates, the gap between the right to an abortion and the ability to obtain one will only continue to widen.
About the Author
